323 related articles for article (PubMed ID: 17551535)
21. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
22. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
Gorai I;
Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
[TBL] [Abstract][Full Text] [Related]
23. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence.
Col NF; Bowlby LA; McGarry K
Minerva Med; 2005 Oct; 96(5):331-42. PubMed ID: 16227948
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
25. An integrated approach: bisphosphonate management for the treatment of osteoporosis.
Owens G; Jackson R; Lewiecki EM
Am J Manag Care; 2007 Dec; 13 Suppl 11():S290-308; quiz S309-12. PubMed ID: 18095779
[TBL] [Abstract][Full Text] [Related]
26. [Bone and Men's Health. Male osteoporosis].
Mori S
Clin Calcium; 2010 Feb; 20(2):182-8. PubMed ID: 20118509
[TBL] [Abstract][Full Text] [Related]
27. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
28. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
29. [Bone diseases with Pain. Osteoporosis].
Hayashi Y
Clin Calcium; 2007 Apr; 17(4):606-12. PubMed ID: 17404492
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
31. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
32. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
Soen S
Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
[TBL] [Abstract][Full Text] [Related]
33. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
34. [The successful development of bisphosphonates in the therapy of osteoporosis].
Fassbender WJ; Stumpf UC; Kurth A
Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
[TBL] [Abstract][Full Text] [Related]
35. Secondary prevention of osteoporosis: Calcium, Vitamin D and bisphosphonate prescribing following distal radial fracture.
Talbot JC; Elener C; Praveen P; Shaw DL
Injury; 2007 Nov; 38(11):1236-40. PubMed ID: 17572417
[TBL] [Abstract][Full Text] [Related]
36. [Bisphosphonate and mechanical stress on bone].
Endo I; Matsumoto T
Clin Calcium; 2008 Sep; 18(9):1321-6. PubMed ID: 18758038
[TBL] [Abstract][Full Text] [Related]
37. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
38. [Activate vitamin D3 or bisphosphonate in glucocorticoid-induced osteoporosis].
Imanishi Y; Nishizawa Y
Clin Calcium; 2006 Nov; 16(11):1844-50. PubMed ID: 17079851
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.
Jansen JP; Bergman GJ; Huels J; Olson M
Semin Arthritis Rheum; 2011 Feb; 40(4):275-84.e1-2. PubMed ID: 20828791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
